Given the activity of venetoclax in MCL, a phase 2 trial validated that dual targeting of BTK and BCL-2 with ibrutinib and venetoclax could significantly improve treatment outcomes in patients with relapsed or refractory MCL. This evidence concerns the gene BTK and mantle cell lymphoma.